Drug Trial Radar · NCT06703021
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Dec 20, 2024
Primary completion
Jan 12, 2026
Study completion Jan 12, 2026
Sponsor
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.
Conditions
- Obesity
- Overweight
- Chronic Weight Management
Interventions
aleniglipron or placeboDrug
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placeboDrug
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placeboDrug
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placeboDrug
Drug: aleniglipron administered orally; Drug: placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline and week 44
- Adverse events of special interestTime frame: Baseline and week 44
- Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysisTime frame: Baseline and week 44
- Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS durationTime frame: Baseline and week 44
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperatureTime frame: Baseline and week 44
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
ACCESS II Research Site
Glendale, California
ACCESS II Research Site
Montclair, California
ACCESS II Research Site
Valparaiso, Indiana
ACCESS II Research Site
West Des Moines, Iowa
ACCESS II Research Site
Medford, Oregon
ACCESS II Research Site
East Greenwich, Rhode Island
ACCESS II Research Site
North Charleston, South Carolina
ACCESS II Research Site
Dallas, Texas
ACCESS II Research Site
San Antonio, Texas
ACCESS II Research Site
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.